Actively Recruiting
Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Phase I Pilot Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
Led by University of Pennsylvania · Updated on 2025-11-19
70
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the biodistribution, metabolism, excretion, and brain uptake of a new radiotracer called 11C HY-2-15. This radiotracer is designed to measure abnormal alpha-synuclein deposits in the brains of people with Multiple System Atrophy (MSA). The study also compares these results with people having Parkinson disease (PD), progressive supranuclear palsy (PSP), and healthy volunteers. This multicenter project is funded by an NIH U19 grant and is coordinated by the University of Pennsylvania alongside several other institutions.
CONDITIONS
Brief Title
Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women clinically diagnosed with Multiple System Atrophy, Parkinson disease, progressive supranuclear palsy, or healthy controls
- Adults aged 40 to 80 years
- Willing and able to provide written informed consent
- Diagnosis confirmed by consensus committee for PD, MSA, PSP, or healthy control
- Participants may agree to brain donation but it is not required for participation
You will not qualify if you...
- Females who are pregnant or breastfeeding
- Forms of parkinsonism other than PD, PSP, and MSA
- Major psychiatric disorders such as schizophrenia or bipolar disorder
- History of significant or ongoing alcohol or substance abuse
- Inability to tolerate imaging, arterial line, IV placement, or blood draws
- Contraindications to MRI, such as non-compatible implanted medical devices
- PSP and MSA subjects with prior positive beta-amyloid PET scan or positive CSF Alzheimer's disease biomarkers
- Any medical condition that could compromise safety or participation as assessed by a physician or investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo diagnostic imaging including a 2-hour PET scan using the radiotracer 11C-HY-2-15, and may also have a brain MRI and Amyloid PET scan to assess brain uptake and biodistribution of the tracer.
1 imaging session (in-person)
Duration - Up to 4 weeks
Participants are monitored for safety and tolerability following the imaging procedures, including neurological assessments and observation for any adverse events.
Follow-up visits as needed within 4 weeks
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
E
Erin o Schubert
M
Mary Hansbury
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here